Study Metrics
Covariates
4
PICO Comparisons
2
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Chen |
| Publication Year: | 2022 |
| DOI: | https://doi.org/10.1200/cci.21.00195 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | University of Florida, Cornell University, Duke University, Wake Forest School of Medicine |
| Funding: | Declared: Public |
| Funding Institutions: | Supported by National Cancer Institute R21CA253394; National Cancer Institute R01CA246418. |
Study Context
| Disease: | Colorectal Cancer |
| Disease Category: | Oncology |
| Data Type: | Registry |
| Number of Data Sources: | 1 |
| Geography: | US |
| Eligible Sample: | 49948.0 |
| Number of Emulations: | 2 |
| Number of Treatments: | 2 |
Analytical Methods
| Matching Method: | PS matching |
| Analysis Method: | Cox PH |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | Cutsem et al. |
| Registration Number: | NCT00154102 |
| Target Trial DOI: | https://doi.org/10.1200/jco.2010.33.5091 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
Death
Cutsem et al.
HR
Efficacy
Population
Patients with metastatic colorectal cancer
Intervention
Cetuximab + FOLFIRI
Comparison
FOLFIRI alone
Outcome
Death
RCT Result
0.93
95% CI: [0.81, 1.07]
vs
TTE Result
0.86
95% CI: [0.68, 1.07]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Same Direction
Both point to similar conclusion
Both point to similar conclusion
Death
Peeters et al.
HR
Efficacy
Population
Patients with metastatic colorectal cancer
Intervention
Panitumumab + FOLFIRI
Comparison
FOLFIRI alone
Outcome
Death
RCT Result
0.96
95% CI: [0.75, 1.23]
vs
TTE Result
0.89
95% CI: [0.68, 1.38]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Same Direction
Both point to similar conclusion
Both point to similar conclusion
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | Tempus, Pfizer, Bristol Myers Squibb, Merck, AstraZeneca/MedImmune, Lilly, Bayer, Incyte, Ipsen, Seattle Genetics, Genentech, Astellas Pharma, BioMed Valley Discoveries, GlaxoSmithKline, Amgen, OncoC4, IBM, Boehringer Ingelheim, Synyi Tech, Air Liquide, Sanofi, Johnson & Johnson, Gilead Sciences, Celgene, Athenex |
| Funding Source: | Declared: Public |
| Funding Institutions: | Supported by National Cancer Institute R21CA253394; National Cancer Institute R01CA246418. |